| Description | SJM-3 is a positive allosteric modulator of various isoforms of the GABAA receptor, specifically binding to the high-affinity benzodiazepine binding site located at the α+/γ- subunit interface. |
| In vitro | SJM-3 binds at the high-affinity benzodiazepine binding site at theα+/γ- subunit interface but effects its action through another site presumably located within the transmembrane domain. The binding affinity of SJM-3 at wild type receptors is determined by displacement of [ 3 H]-Flunitrazepam and [ 3 H]-Ro15-1788 and indicates a K i of SJM-3 amounting to 218±70 nM and 242±38 nM, respectively[1]. |
| molecular weight | 354.4 |
| Molecular formula | C18H15FN4OS |
| CAS | 1234977-97-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Simon J Middendorp, et al. Positive modulation of synaptic and extrasynaptic GABAA receptors by an antagonist of the high affinity benzodiazepine binding site. Neuropharmacology. 2015 Aug;95:459-67. |